Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
AUS.: +61-2-4786-0457
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Global Primary Sclerosing Cholangitis Market Size Share Forecast 2025

  • Purchase Options

 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.
Market Dynamics
Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.
However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.
Key features of the study:

This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same
It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market

Detailed Segmentation:

Global Primary Sclerosing Cholangitis Market, By Drug:

BTT1023
GS-9674
NGM282
OCA
Cenicriviroc
LUM001
DUR928
norUDCA
HTD1801
IDN-7314
STP705

Global Primary Sclerosing Cholangitis Market, By Region:

North America

Regional Overview


Latin America

Regional Overview


Europe

Regional Overview


Asia Pacific

Regional Overview


Middle East

Regional Overview


Africa

Regional Overview




Company Profiles

Acorda Therapeutics, Inc.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments


Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.



“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Overview
o Optimistic, Likely and Pessimistic Overview
3. Market Dynamics, Pipeline, and PEST Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o PEST Analysis
o Pipeline Analysis
o Initiatives Focusing On PSC Support And Research
o Reason For Phase 3 Drug Withdrawal
o Challenges Faced by Orphan Drug Candidates
o Epidemiology
4. Global Primary Sclerosing Cholangitis Market, By Drug
o Introduction
o BTT1023
o Research Details
o GS-9674
o Research Details
o NGM282
o Research Details
o OCA
o Research Details
o Cenicriviroc
o Research Details
o LUM001
o Research Details
o DUR928
o Research Details
o norUDCA
o Research Details
o HTD1801
o Research Details
o IDN-7314
o Research Details
o STP705
o Research Details
5. Global Primary Sclerosing Cholangitis Market, By Region
o Introduction
o North America
o Regional Overview
o Latin America
o Regional Overview
o Europe
o Regional Overview
o Asia Pacific
o Regional Overview
o Middle East
o Regional Overview
o Africa
o Regional Overview
6. Competitive Landscape
o Company Profiles
o Acorda Therapeutics, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Gilead Sciences, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o NGM Biopharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Intercept Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Dr. Falk Pharma GmbH
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Allergan Plc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Shire Plc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Durect Corporation
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Conatus Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Sirnaomics, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Shenzhen HighTide Biopharmaceutical Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
7. Section
o References
o Research Methodology
o About us and Sales Contact

 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us